1. Home
  2. PRGO vs URGN Comparison

PRGO vs URGN Comparison

Compare PRGO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perrigo Company plc

PRGO

Perrigo Company plc

N/A

Current Price

$16.23

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$26.12

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRGO
URGN
Founded
1887
2004
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
PRGO
URGN
Price
$16.23
$26.12
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
$18.00
★ $60.71
AVG Volume (30 Days)
★ 2.2M
1.2M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
★ 7.17%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$800,000.00
★ $1,128,000.00
Revenue This Year
N/A
$190.44
Revenue Next Year
N/A
$69.25
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.23
$16.50
52 Week High
$17.02
$50.81

Technical Indicators

Market Signals
Indicator
PRGO
URGN
Relative Strength Index (RSI) 56.47 27.59
Support Level $9.93 $23.51
Resistance Level $16.79 $27.76
Average True Range (ATR) 0.70 2.05
MACD -0.02 -0.35
Stochastic Oscillator 60.79 13.91

Price Performance

Historical Comparison
PRGO
URGN

About PRGO Perrigo Company plc

Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: